Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies

Document Sample
Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies Powered By Docstoc
					          Anticonvulsants Market to 2016 - Cost Advantage and
        Dosage Convenience Provided by Generic Anticonvulsants
         Will Limit Commercial Opportunities for Novel Therapies
      Reference Code: GBIHC070MR                                                                                                     Publication Date: January 2011


                                         Patent Expiries of the Leading Anticonvulsants Followed by Generics Erosions Will Decline
                                         the Anticonvulsants Market by a CAGR of 0.1% in The Future

     Generic erosion will                Various anticonvulsants, both branded and off-label are being used for the treatment of many
     cause anticonvulsant                indications such as epilepsy, fibromyalgia, migraine, neuropathic pain, bipolar disorder and anxiety.
     market to decline at a              The patents of leading anticonvulsants such as Topamax (topiramate), Trileptal (oxcarbazepine),
     CAGR of 0.1%.                       Depakote (divalproex sodium), Keppra (levetiracetam), Lamictal (lamotrigine) and Tegretol
                                         (carbamazepine) expired in 2007-2008. The wide applicability of the anticonvulsants for
                                         management of the various indications has caused the emergence of generics for these
                                         anticonvulsants in the market. This generic erosion will cause decline in the anticonvulsant market
                                         in the future.

                                          Anticonvulsant Market, Global, Revenue Forecasts ($m), 2001-2016

                                                               12,000
                                                                         Anticonvulsant market is expected to decline in the forecasted period
                                                                        at a CAGR of 0.1% due to patent expiry of the leading anticonvulsants
                                                                        followed by generic erosion.

                                                               10,000
                                                                                                                                          CAGR (2001-2009) :1.3 %
                                                                                                                                          CAGR (2009-2016) : (0.1)%

                                                                8,000
                                                Revenue ($m)




                                                                6,000




                                                                4,000




                                                                2,000




                                                                   0
                                                                                 2001                          2010                              2016

                                          Source: GBI Research, MedScape, CDC
                                          Note : CAGR stands for Compound Annual Growth Rate




Anticonvulsants Market to 2016 - Cost Advantage and Dosage                                                                            GBIHC070MR /Published JAN 2011
Convenience Provided by Generic Anticonvulsants Will Limit
Commercial Opportunities for Novel Therapies                                                                                                                          Page 1
                                                                                            © GBI Research. This is a licensed product and is not to be photocopied
                                         Strong Anticonvulsants Product Pipeline Will Drive the Anticonvulsant Market in Future
                                         The anticonvulsants product pipeline consists of 23 new molecules in the various stages of clinical
                                         trials, as indicated below.

                                          Anticonvulsant Market, Global Product Pipeline by Phase (%), 2010
                                                                                                         Discovery
                                                                                                           13%




                                                                    Phase III                                               Phase I
                                                                     44%                                                     17%




                                                                                                              Phase II
                                                                                                               26%
                                                                                            Total = 23


                                          Source: GBI Research, Company Websites



                                         Two anticonvulsants, Fosphenytoin and Stedesa have been filed in the US with FDA and 44% of
                                         the total anticonvulsants product pipeline is in Phase III clincal studies. The majority of these
                                         molecules are being studied as monotherapies for the treatment of epilepsy.The expected launch
                                         of these new anticonvusants in the future is expected to to stabilize the declining anticonvulsant
                                         market.
                                         Lyrica Will Be a Market Leader in Anticonvulsants Market in Future
                                         Lyrica (pregabalin) is the branded anriconvulsant product of Pfizer.Lyrica is indicated for the
                                         treatment of the epilepsy, fibromyalgia and neuropathic pain. Lyrica along with Neurontin
                                         (gabapentin) is the first line of therapy for the treatment of neuropathic pain, especially when
                                         tricyclic antidepressants are contraindicated. Lyrica is the only anticonvulsant which has been
                                         approved for the treatment of fibromyalgia. Lyrica generated revenue of $2.6 billion and $2.8 billion
                                         for Pfizer, in 2008 and 2009 respectively.
                                         The increasing uptake of Lyrica for the treatment of neuropathic pain and fibromyalgia is expected
                                         to make Lyrica the market leader in the anticonvulsant market in future.




Anticonvulsants Market to 2016 - Cost Advantage and Dosage                                                               GBIHC070MR /Published JAN 2011
Convenience Provided by Generic Anticonvulsants Will Limit
Commercial Opportunities for Novel Therapies                                                                                                     Page 2
                                                                                © GBI Research. This is a licensed product and is not to be photocopied
                                         1         Table of Contents
                                         1   Table of Contents ........................................................................................................................ 3
                                             1.1    List of Tables..................................................................................................................... 6
                                             1.2    List of Figures ................................................................................................................... 8
                                         2   Anticonvulsant Market to 2016 – Introduction ............................................................................ 10
                                             2.1    GBI Research Report Guidance ..................................................................................... 13
                                         3   Anticonvulsant Market to 2016 – Market Overview.................................................................... 14
                                             3.1    Introduction ..................................................................................................................... 14
                                             3.2    Revenue Forecasts for the Global Anticonvulsant Market .............................................. 14
                                                3.2.1    Revenue .................................................................................................................. 14
                                                3.2.2    Annual Cost of Treatment (ACT) ............................................................................. 15
                                         4   Anticonvulsant Market to 2016 – Geographical Landscape ....................................................... 16
                                             4.1    Revenue Analysis by Geography .................................................................................... 16
                                             4.2    The US ............................................................................................................................ 17
                                                4.2.1    Revenue .................................................................................................................. 17
                                                4.2.2    Annual Cost of Treatment ........................................................................................ 18
                                             4.3    Top Five Countries of Europe ......................................................................................... 19
                                                4.3.1    Revenue .................................................................................................................. 19
                                                4.3.2    Annual Cost of Treatment ........................................................................................ 20
                                             4.4    Japan .............................................................................................................................. 21
                                                4.4.1    Revenue .................................................................................................................. 21
                                                4.4.2    Annual Cost of Treatment ........................................................................................ 22
                                         5   Anticonvulsant Market to 2016 – Therapeutic Landscape ........................................................ 23
                                             5.1    Anticonvulsant Market for Bipolar Disorder ..................................................................... 23
                                                5.1.1    Introduction .............................................................................................................. 23
                                                5.1.2    Revenue .................................................................................................................. 24
                                                5.1.3    Annual Cost of Treatment ........................................................................................ 26
                                                5.1.4    Treatment Usage Patterns ...................................................................................... 27
                                             5.2    Drivers and Barriers to the Anticonvulsant Market for Bipolar Disorder .......................... 32
                                                5.2.1    Drivers for the Bipolar Disorder Market ................................................................... 32
                                                5.2.2    Barriers for the Disorder Market .............................................................................. 32
                                             5.3    Anticonvulsant Market for Neuropathic Pain ................................................................... 33
                                                5.3.1    Introduction .............................................................................................................. 33
                                                5.3.2    Revenue .................................................................................................................. 34
                                                5.3.3    Annual Cost of Treatment ........................................................................................ 36
                                                5.3.4    Treatment Usage Patterns ...................................................................................... 37
                                             5.4    Drivers and Barriers to Anticonvulsant Market of Neuropathic Pain ................................ 42
                                                5.4.1    Drivers for Neuropathic Pain Market ........................................................................ 42
                                                5.4.2    Restraints for Neuropathic Pain Market ................................................................... 42
                                             5.5    Anticonvulsant Market for Fibromyalgia .......................................................................... 43
                                                5.5.1    Introduction .............................................................................................................. 43
                                                5.5.2    Revenue .................................................................................................................. 44
                                                5.5.3    Annual Cost of Treatment ........................................................................................ 46
                                                5.5.4    Treatment Usage Patterns ...................................................................................... 47
                                             5.6    Drivers and Barriers to Anticonvulsant Market of Fibromyalgia....................................... 53
                                                5.6.1    Drivers for the Fibromyalgia Therapeutics Market ................................................... 53
                                                5.6.2    Barriers for the Fibromyalgia Therapeutics Market .................................................. 53
                                             5.7    Anticonvulsant Market for Migraine ................................................................................. 54
                                                5.7.1    Introduction .............................................................................................................. 54
                                                5.7.2    Revenue .................................................................................................................. 55
                                                5.7.3    Annual Cost of Treatment ........................................................................................ 57
                                                5.7.4    Treatment Usage Patterns ...................................................................................... 58
                                             5.8    Drivers and Barriers to Anticonvulsant Market for Migraine ............................................ 63
                                                5.8.1    Drivers for the Migraine Market ............................................................................... 63


Anticonvulsants Market to 2016 - Cost Advantage and Dosage                                                                                 GBIHC070MR /Published JAN 2011
Convenience Provided by Generic Anticonvulsants Will Limit
Commercial Opportunities for Novel Therapies                                                                                                                                     Page 3
                                                                                           © GBI Research. This is a licensed product and is not to be photocopied
                                              5.8.2    Barriers for the Migraine Market .............................................................................. 63
                                           5.9    Anticonvulsant Market for Epilepsy ................................................................................. 64
                                              5.9.1    Introduction .............................................................................................................. 64
                                              5.9.2    Revenue .................................................................................................................. 64
                                              5.9.3    Annual Cost of Treatment ........................................................................................ 67
                                              5.9.4    Treatment Usage Patterns ...................................................................................... 68
                                           5.10 Drivers and Barriers to Anticonvulsant Market for Epilepsy ............................................ 73
                                              5.10.1 Drivers to Anticonvulsant Market for Epilepsy ......................................................... 73
                                              5.10.2 Barriers to Anticonvulsant Market for Epilepsy ........................................................ 74
                                         6 Anticonvulsant Market to 2016 – Product Pipeline Analysis ...................................................... 75
                                           6.1    Introduction ..................................................................................................................... 75
                                              6.1.1    Research and Development Pipeline ...................................................................... 75
                                           6.2    Profiles of Promising Anticonvulsant Drugs .................................................................... 78
                                              6.2.1    Brivaracetam ........................................................................................................... 78
                                              6.2.2    Clonazepam + Levetiracetam .................................................................................. 78
                                              6.2.3    Epliga ...................................................................................................................... 78
                                              6.2.4    Potiga ...................................................................................................................... 79
                                              6.2.5    USL 255 .................................................................................................................. 79
                                              6.2.6    Vanquix ................................................................................................................... 79
                                              6.2.7    Trokesa ................................................................................................................... 80
                                              6.2.8    E2007 ...................................................................................................................... 80
                                              6.2.9    Vimpat (Lacosamide) ............................................................................................... 80
                                         7 Anticonvulsant Market to 2016 – Competitive Landscape ......................................................... 81
                                           7.1    Market Share Analysis .................................................................................................... 81
                                           7.2    Pfizer Inc. ........................................................................................................................ 82
                                              7.2.1    Company Overview ................................................................................................. 82
                                              7.2.2    Business Overview .................................................................................................. 82
                                              7.2.3    SWOT Analysis ....................................................................................................... 83
                                           7.3    UCB Group ..................................................................................................................... 83
                                              7.3.1    Company Overview ................................................................................................. 83
                                              7.3.2    Business Overview .................................................................................................. 83
                                              7.3.3    SWOT Analysis ....................................................................................................... 84
                                           7.4    Johnson & Johnson (J&J) ............................................................................................... 85
                                              7.4.1    Company Overview ................................................................................................. 85
                                              7.4.2    Business Overview .................................................................................................. 85
                                              7.4.3    SWOT Analysis ....................................................................................................... 86
                                           7.5    GlaxoSmithKline plc ........................................................................................................ 87
                                              7.5.1    Company Overview ................................................................................................. 87
                                              7.5.2    Business Overview .................................................................................................. 87
                                              7.5.3    SWOT Analysis ....................................................................................................... 88
                                           7.6    Abbott Laboratories ......................................................................................................... 88
                                              7.6.1    Company Overview ................................................................................................. 88
                                              7.6.2    Business Overview .................................................................................................. 89
                                              7.6.3    SWOT Analysis ....................................................................................................... 89
                                           7.7    Novartis AG..................................................................................................................... 90
                                              7.7.1    Company Overview ................................................................................................. 90
                                              7.7.2    Business Overview .................................................................................................. 90
                                              7.7.3    SWOT Analysis ....................................................................................................... 91
                                         8 Anticonvulsant Market to 2016 – M&A Landscape .................................................................... 92
                                           8.1    M&A Deals 2005-2010 .................................................................................................... 92
                                              8.1.1    Deal Summary ......................................................................................................... 93
                                              8.1.2    Deals by Value ........................................................................................................ 96
                                              8.1.3    Deals by Geography ................................................................................................ 97
                                           8.2    Licensing Deals 2005-2010............................................................................................. 98
                                              8.2.1    Summary of Licensing Deals (2009-2010) .............................................................. 99

Anticonvulsants Market to 2016 - Cost Advantage and Dosage                                                                                GBIHC070MR /Published JAN 2011
Convenience Provided by Generic Anticonvulsants Will Limit
Commercial Opportunities for Novel Therapies                                                                                                                                   Page 4
                                                                                           © GBI Research. This is a licensed product and is not to be photocopied
                                           8.3    Co-developments Deals 2005-2010 .............................................................................. 100
                                              8.3.1    Summary of Co-development Deals (2009-2010) ................................................. 101
                                         9 Anticonvulsants Market to 2016 – Appendix ........................................................................... 102
                                           9.1    Market Definitions ......................................................................................................... 102
                                           9.2    Abbreviations ................................................................................................................ 102
                                           9.3    Research Methodology ................................................................................................. 103
                                              9.3.1    Coverage ............................................................................................................... 103
                                              9.3.2    Secondary Research ............................................................................................. 103
                                              9.3.3    Primary Research .................................................................................................. 104
                                              9.3.4    Expert Panel Validation ......................................................................................... 106
                                           9.4    Contact Us .................................................................................................................... 106
                                           9.5    Disclaimer ..................................................................................................................... 106
                                           9.6    Sources ......................................................................................................................... 106




Anticonvulsants Market to 2016 - Cost Advantage and Dosage                                                                              GBIHC070MR /Published JAN 2011
Convenience Provided by Generic Anticonvulsants Will Limit
Commercial Opportunities for Novel Therapies                                                                                                                                 Page 5
                                                                                          © GBI Research. This is a licensed product and is not to be photocopied
                                         1.1    List of Tables
                                         Table 1:    Anticonvulsant Market, Global Revenue of Top Selling Anticonvulsants ($m), Approved
                                                     Indications, 2007-2009 ................................................................................................... 11
                                         Table 2:    Anticonvulsant Market, Future Promising Players in Anticonvulsant Market .................. 12
                                         Table 3:    Anticonvulsant Market, Global, Revenue Forecasts ($m), 2001-2009 ........................... 14
                                         Table 4:    Anticonvulsant Market, Global, Revenue Forecasts ($m), 2009-2016 ........................... 14
                                         Table 5:    Anticonvulsant Market, Global, Annual Cost of Treatment ($), 2001-2009 .................... 15
                                         Table 6:    Anticonvulsant Market, Global, Annual Cost of Treatment ($), 2009-2016 .................... 15
                                         Table 7:    Anticonvulsant Market, Global, Revenue Analysis by Geography ($m), 2001-2009 ...... 16
                                         Table 8:    Anticonvulsant Market, Global, Revenue Analysis by Geography ($m), 2009-2016 ...... 16
                                         Table 9:    Anticonvulsant Market, The US, Revenue ($m) , 2001-2009 ......................................... 17
                                         Table 10:   Anticonvulsant Market, The US, Revenue Forecasts ($m), 2009-2016 ......................... 17
                                         Table 11:   Anticonvulsant Market, The US, Annual Cost of Treatment($), 2001-2009 .................... 18
                                         Table 12:   Anticonvulsant Market, The US, Annual Cost of Treatment ($), 2009-2016 ................... 18
                                         Table 13:   Anticonvulsant Market, Top Five Countries of Europe, Revenue ($m), 2001-2009 ....... 19
                                         Table 14:   Anticonvulsant Market, Top Five Countries of Europe, Revenue Forecasts ($m),
                                                     2009-2016 ...................................................................................................................... 19
                                         Table 15:   Anticonvulsant Market, Top Five Countries of Europe, Annual Cost of Treatment ($),
                                                     2001-2009 ...................................................................................................................... 20
                                         Table 16:   Anticonvulsant Market, Top Five Countries of Europe, Annual Cost of Treatment ($),
                                                     2009-2016 ...................................................................................................................... 20
                                         Table 17:   Anticonvulsant Market, Japan, Revenue ($m), 2001-2009 ............................................ 21
                                         Table 18:   Anticonvulsant Market, Japan, Revenue Forecast ($m), 2009-2016.............................. 21
                                         Table 19:   Anticonvulsant Market, Japan, Annual Cost of Treatment ($), 2001-2009 ..................... 22
                                         Table 20:   Anticonvulsant Market, Japan, Annual Cost of Treatment ($), 2009-2016 ..................... 22
                                         Table 21:   Anticonvulsant Market, Bipolar Disorder, Global, Revenue ($m), 2001-2009 ................ 24
                                         Table 22:   Anticonvulsant Market, Bipolar Disorder, Global Revenue Forecast ($m), 2009-2016 . 24
                                         Table 23:   Anticonvulsant Market, Bipolar Disorder, Revenue by Geography ($m), 2001-2009 ..... 25
                                         Table 24:   Anticonvulsant Market, Bipolar Disorder, Revenue by Geography ($m),2009-2016 ...... 25
                                         Table 25:   Anticonvulsant Market, Bipolar Disorder, Annual Cost of Treatment by Geography ($),
                                                     2001-2009 ...................................................................................................................... 26
                                         Table 26:   Anticonvulsant Market, Bipolar Disorder, Annual Cost of Treatment by Geography ($),
                                                     2009-2016 ...................................................................................................................... 26
                                         Table 27:   Anticonvulsant Market, Bipolar Disorder, Global Treatment Usage Patterns (Million),
                                                     2001-2009 ...................................................................................................................... 27
                                         Table 28:   Anticonvulsant Market, Bipolar Disorder, Global Treatment Usage Patterns (Million),
                                                     2009-2016 ...................................................................................................................... 28
                                         Table 29:   Anticonvulsant Market, Neuropathic Pain, Global Revenue ($m), 2001-2009 ............... 34
                                         Table 30:   Anticonvulsant Market, Neuropathic Pain, Global Revenue Forecast ($m), 2009-2016 34
                                         Table 31:   Anticonvulsant Market, Neuropathic Pain, Revenue by Geography, ($m),2001-2009 ... 35
                                         Table 32:   Anticonvulsant Market, Neuropathic Pain, Revenue by Geography ($m), 2009-2016 ... 35
                                         Table 33:   Anticonvulsant Market for Neuropathic Pain, Global, Annual Cost of Treatment ($),
                                                     2001-2009 ...................................................................................................................... 36
                                         Table 34:   Anticonvulsant Market for Neuropathic Pain, Global, Annual Cost of Treatment($), 2009-
                                                     2016 ............................................................................................................................... 36
                                         Table 35:   Anticonvulsant Market, Neuropathic Pain, Global Treatment Usage Patterns (Million),
                                                     2001-2009 ...................................................................................................................... 37
                                         Table 36:   Anticonvulsant Market, Neuropathic Pain, Global Treatment Usage Patterns (Million),
                                                     2009-2016 ...................................................................................................................... 38
                                         Table 37:   Anticonvulsant Market, Fibromyalgia, Global Revenue Forecasts ($m), 2001-2009 ..... 44
                                         Table 38:   Anticonvulsant Market, Fibromyalgia, Global Revenue Forecasts ($m), 2009-2016 ..... 44
                                         Table 39:   Anticonvulsant Market, Fibromyalgia, Revenue by Geography ($m),2001-2009 ........... 45
                                         Table 40:   Anticonvulsant Market, Fibromyalgia, Revenue by Geography ($m),2009-2016 ........... 45
                                         Table 41:   Anticonvulsant Market, Fibromyalgia, Annual Cost of Treatment by Geography ($),
                                                     2001-2009 ...................................................................................................................... 46
                                         Table 42:   Anticonvulsant Market, Fibromyalgia, Annual Cost of Treatment by Geography ($),
                                                     2009-2016 ...................................................................................................................... 47
                                         Table 43:   Anticonvulsant Market, Fibromyalgia, Treatment Usage Patterns (Million), 2001-2009 48
                                         Table 44:   Anticonvulsant Market, Fibromyalgia, Treatment Usage Patterns (Million), 2009-2016 48
                                         Table 45:   Anticonvulsant Market, Migraine, Global Revenue Forecasts ($m), 2001-2009 ............ 55
                                         Table 46:   Anticonvulsant Market, Migraine, Global Revenue Forecasts ($m), 2009-2016 ............ 55
                                         Table 47:   Anticonvulsant Market, Migraine, Revenue by Geography ($m), 2001-2009 ................. 56

Anticonvulsants Market to 2016 - Cost Advantage and Dosage                                                                                GBIHC070MR /Published JAN 2011
Convenience Provided by Generic Anticonvulsants Will Limit
Commercial Opportunities for Novel Therapies                                                                                                                                     Page 6
                                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                         Table 48:   Anticonvulsant Market, Migraine, Revenue by Geography ($m),2009-2016 .................. 56
                                         Table 49:   Anticonvulsant Market, Migraine, Global, Annual Cost of Treatment ($), 2001-2009 .... 57
                                         Table 50:   Anticonvulsant Market, Migraine, Global, Annual Cost of Treatment ($), 2009-2016 .... 57
                                         Table 51:   Anticonvulsant Market, Migraine, Global Treatment Usage Patterns (Million), 2001-2009
                                                     ....................................................................................................................................... 58
                                         Table 52:   Anticonvulsant Market, Migraine, Global Treatment Usage Patterns (Million), 2009-2016
                                                     ....................................................................................................................................... 58
                                         Table 53:   Anticonvulsant Market, Epilepsy, Global Revenue Forecasts ($m), 2001-2009 ............. 65
                                         Table 54:   Anticonvulsant Market, Epilepsy, Global Revenue Forecasts ($m), 2009-2016 ............. 65
                                         Table 55:   Anticonvulsant Market, Epilepsy, Revenue by Geography, ($m),2001-2009 ................. 66
                                         Table 56:   Anticonvulsant Market, Epilepsy, Revenue by Geography, ($m),2009-2016 ................. 66
                                         Table 57:   Anticonvulsant Market for Epilepsy, Global, Annual Cost of Treatment ($), 2001-2009 67
                                         Table 58:   Anticonvulsant Market for Epilepsy, Global, Annual Cost of Treatment ($), 2009-2016 67
                            
				
DOCUMENT INFO
Description: Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies Summary GBI Research, the leading business intelligence provider, has released its latest research, “Anticonvulsants Market to 2016 –Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies”, which provides insights into global anticonvulsant market and market forecast until 2016. Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the top five therapeutic indications for which often anticonvulsants are prescribed which includes epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder. The report also examines the Global anticonvulsant treatment usage patterns for the covered indication. In addition, the report also includes insights into the anticonvulsant R&D pipeline. GBI Research analysis shows that the overall global anticonvulsant market for the five indications epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder is valued at $7.75 billion in 2009. The market is expected to witness a decline at a CAGR of 0.1% for the forecast period and will reach $7.7 billion by 2016. Patent expiries of leading anticonvulsant followed by generic erosions are the main reason for decline in anticonvulsant market. However expected launch of new anticonvulsants is expected to stabilize the market in future. The US was the largest region for the anticonvulsant market in terms of revenue, accounting for 52% followed by Top five countries of Europe and Japan which contributed 36% and 12% respectively. The top pharmaceutical companies in anticonvulsant market companies – Pfizer, Novartis, Abbott, UCB, Johnson & Johnson and Glax
BUY THIS DOCUMENT NOW PRICE: $3500 100% MONEY BACK GUARANTEED
PARTNER GBI Research
GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.